Guideline for prescribing opioids for chronic pain by unknown
CDC’s Guideline for Prescribing Opioids for Chronic Pain is intended to improve communication between providers and 
patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain 
treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder and overdose. 
The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.
Nonpharmacologic therapy and nonopioid pharmacologic therapy 
are preferred for chronic pain. Clinicians should consider opioid 
therapy only if expected benefits for both pain and function are 
anticipated to outweigh risks to the patient. If opioids are used, 
they should be combined with nonpharmacologic therapy and 
nonopioid pharmacologic therapy, as appropriate.
Before starting opioid therapy for chronic pain, clinicians 
should establish treatment goals with all patients, including 
realistic goals for pain and function, and should consider how 
opioid therapy will be discontinued if benefits do not outweigh 
risks. Clinicians should continue opioid therapy only if there is 
clinically meaningful improvement in pain and function that 
outweighs risks to patient safety. 
Before starting and periodically during opioid therapy, clinicians 
should discuss with patients known risks and realistic benefits 
of opioid therapy and patient and clinician responsibilities for 
managing therapy.





• Opioids are not first-line or routine 
therapy for chronic pain
• Establish and measure goals for pain 
and function
• Discuss benefits and risks and 
availability of nonopioid therapies with 
patient
IMPROVING PRACTICE THROUGH RECOMMENDATIONS
LEARN MORE  |  www.cdc.gov/drugoverdose/prescribing/guideline.html
GUIDELINE FOR PRESCRIBING  
OPIOIDS FOR CHRONIC PAIN
When starting opioid therapy for chronic pain, clinicians should prescribe 
immediate-release opioids instead of extended-release/long-acting (ER/LA) 
opioids.
When opioids are started, clinicians should prescribe the lowest effective dosage. 
Clinicians should use caution when prescribing opioids at any dosage, should 
carefully reassess evidence of individual benefits and risks when considering 
increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should 
avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate 
dosage to ≥90 MME/day.
Long-term opioid use often begins with treatment of acute pain. When opioids 
are used for acute pain, clinicians should prescribe the lowest effective dose of 
immediate-release opioids and should prescribe no greater quantity than needed 
for the expected duration of pain severe enough to require opioids. Three days or 
less will often be sufficient; more than seven days will rarely be needed.
Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks 
of starting opioid therapy for chronic pain or of dose escalation. Clinicians 
should evaluate benefits and harms of continued therapy with patients every 3 
months or more frequently. If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and work with patients to 
taper opioids to lower dosages or to taper and discontinue opioids.










ASSESSING RISK AND ADDRESSING HARMS OF OPIOID USE
Before starting and periodically during continuation of opioid therapy, clinicians 
should evaluate risk factors for opioid-related harms. Clinicians should 
incorporate into the management plan strategies to mitigate risk, including 
considering offering naloxone when factors that increase risk for opioid overdose, 
such as history of overdose, history of substance use disorder, higher opioid 
dosages (≥50 MME/day), or concurrent benzodiazepine use, are present. 
Clinicians should review the patient’s history of controlled substance prescriptions 
using state prescription drug monitoring program (PDMP) data to determine 
whether the patient is receiving opioid dosages or dangerous combinations that 
put him or her at high risk for overdose. Clinicians should review PDMP data when 
starting opioid therapy for chronic pain and periodically during opioid therapy for 
chronic pain, ranging from every prescription to every 3 months.
When prescribing opioids for chronic pain, clinicians should use urine drug testing 
before starting opioid therapy and consider urine drug testing at least annually to 
assess for prescribed medications as well as other controlled prescription drugs and 
illicit drugs.
Clinicians should avoid prescribing opioid pain medication and benzodiazepines 
concurrently whenever possible.
Clinicians should offer or arrange evidence-based treatment (usually medication-
assisted treatment with buprenorphine or methadone in combination with 
behavioral therapies) for patients with opioid use disorder.
CLINICAL REMINDERS
• Use immediate-release opioids 
when starting
• Start low and go slow
• When opioids are needed for 
acute pain, prescribe no more 
than needed
• Do not prescribe ER/LA opioids 
for acute pain
• Follow-up and re-evaluate risk 
of harm; reduce dose or taper 
and discontinue if needed  
CLINICAL REMINDERS
• Evaluate risk factors for  
opioid-related harms
• Check PDMP for high dosages 
and prescriptions from other 
providers
• Use urine drug testing to identify 
prescribed substances and 
undisclosed use 
• Avoid concurrent benzodiazepine 
and opioid prescribing
• Arrange treatment for opioid use 
disorder if needed
LEARN MORE  |  www.cdc.gov/drugoverdose/prescribing/guideline.html
